Differentiating therapy with all-trans retinoic acid in acute myeloid leukemia

Leukemia

Volumn 10, Issue SUPPL. 1, 1996, Pages

  Tallman, Martin S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

All trans retinoic acid; AML; ATRA; Differentiating; Leukemia; Vitamin A

Indexed keywords

ALITRETINOIN; CYTARABINE; CYTOCHROME P450; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RETINOIC ACID; RETINOID;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; LEUKEMIA REMISSION; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029965522     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Huang M, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
2. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990; 76: 1704-1709.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991; 324: 1385-1393.
4. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr. All-trans retinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994; 120: 278-286.
5. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu WY, Yao XZ, Ling BJ. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
6. Ohno R, Yoshida H, Fukutani H, Naoe T, Oshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Hiraoka A, and the Leukemia Study Group of the Ministry of Health and Welfare. Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 1722-1727.
7. Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992; 80: 2176-2181.
8. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R, and the Japan Adult Leukemia Study Group. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 1202-1206.
9. Elliott S, Taylor K, White S, Rodwell R, Marlton P, Meagher D, Wiley J, Taylor D, Wright S, Timms P. Proof of differentiative mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. Blood 1992; 79: 1916-1919.
10. Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol 1990; 79: 448-453.
11. Wiley JS, Firkin FC. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Leukemia 1995; 9: 774-778.
12. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D. Effect of all-trans retinoic acid in newly diagnosed promyelocytic leukemia: Results of a multicenter randomized trial. Blood 1993; 82: 3241-3249.
13. Tallman MS, Andersen J, Schiffer CA, Appelbaum FR, Feusner JE, Woods WG, Ogden A, Weinstein H, Shepherd L, Rowe JM, Wiernik PH, for ECOG, CALGB, SWOG, CCSG, POG, and NClC-CTG. Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) and cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL). Blood 1995; 86: 488a (abstract).
14. He R, Breitman TR. Retinoic acid inhibits sodium butyrate-induced monocytic differentiation of HL60 cells while synergistically inducing granulocytoid differentiation. Eur J Haematol 1991; 46: 93-100.
15. Chen A, Licht JD, Wu Y, Hellinger N, Scher W, Waxman S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 1994; 84: 2122-2129.
16. Mangelsdorf DF, Loeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol 1984; 98: 391-398.
17. Olsson J, Gullberg U, Ivhed I. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1α,25-dihydroxycholecalci-ferol. Cancer Res 1983; 43: 5862-5867.
18. Peck R, Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U-937 cell lines by cytokines. Eur J Cancer 1991; 27: 53-57.
19. Chun HG, Leyland-Jones B, Hoth D, Shoemaker D Wolpert-DeFilippes M, Grieshaber C, Cradock J, Davignon P, Moon R, Rifkind R, Wittes RE. Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent. Cancer Treat Rep 1986; 70: 991-996.
20. Breitman TR, Ruyi H. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Res 1990; 50: 6268-6273.
21. Jakubowski A, Schuster S, Gabrilove J, Maslak P, Raptis G. All-trans retinoic acid plus granulocyte colony stimulating factor therapy in patients with acute myelogenous leukemia (AML): a pilot study. Blood 1993; 82: 2144a (abstract).
22. Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A, Pisani F, Caravita T, Masi M, Tribalto M. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of poor prognosis acute myeloid leukemia. Leukemia 1995; 9: 1121-1125.
23. Tallman MS, Miller HJ, Zanzig C, Rademaker A, Gordon L, Hakimain D, Variakojis D, Stiff P, French S, Benson AB III. All-trans retinoic acid (ATRA), low-dose cytosine arabinoside (LDAra-C) and granulocyte colony-stimulating factor (G-CSF) in relapsed and refractory acute myelogenous leukemia (AML): an Illinois Cancer Center Phase II Pilot Study. Blood 1994; 84: 1231 a (abstract).
24. Sakashita A, Kizaki M, Pakkala S, Schiller G, Tsuruoka N, Tomosaki R, Cameron JF, Dawson MI, Koeffler HP. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood 1993; 81: 1009-1016.
25. Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A, Koeffler HP. Effects of novel retinoic acid compound, 9-cis-retinoic acid on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-a RNA by HL-60 cells, Blood 1993; 82: 3592-3599.
26. Kizaki M, Nakajima H, Mon S, Koike T, Morikawa M, Ohta M, Saito M, Koeffler HP. Novel retinoic acid, 9-cis retinoic acid, in combination with all-trans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells. Blood 1994; 83: 3289-3297.
27. Bollag W, Peck R. Cancer chemotherapy by combinations of retinoids with cytokines and vitamin D analogs: experimental and clinical results. Ann Oncol 1994; 5: S17-S22.
28. Hellström E, Robert K-H, Gahrton G, Mellstedt H, Lindemalm C, Einhorn S, Bjorkholm M, Grimfors G, Uden AM, Samuelsson J. Therapeutic effects of low-dose cytosine arabinoside, alpha-interfcron, 1α-hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur J Haematol 1988; 40: 449-459.